International Conference on Afghanistan, London (2010)

Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, November 8, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, CAR, Trial of the century, IND, Food, Bio, CD70, Renal cell carcinoma, International Conference on Afghanistan, London (2010), CD20, Society for Immunotherapy of Cancer, Tropism, TGF, Conference, CDMO, Regulation of tobacco by the U.S. Food and Drug Administration, Prostate cancer, R, Engineering, Poster, Goodwill, SITC, Immunotherapy, MCL, Research and development, Annual general meeting, Probability, ACET, Tumor microenvironment, Epitope, NHL, Society, Cancer, PSMA, Patient, Administration, Prognosis, Prostate, CD27, Pharmaceutical industry, Cryptocurrency

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2023.
  • In October 2023, Adicet presented new preclinical data building on the potential of Adicet’s allogeneic gamma delta platform as a promising approach to target prostate cancer.
  • Financial Results for Third Quarter 2023:
    Research and Development (R&D) Expenses: R&D expenses were $26.2 million for the three months ended September 30, 2023, compared to $16.6 million during the same period in 2022.
  • Cash Position: Cash and cash equivalents were $183.3 million as of September 30, 2023, compared to $257.7 million as of December 31, 2022.

Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update

Retrieved on: 
Thursday, November 2, 2023
Research, Society for Hematology and Stem Cells, PIN, Second Half, PFS, Investment, News, SITC, Annual general meeting, Kinetics, ICML, Infection, CAR, International Conference on Afghanistan, London (2010), CD70, Society for Immunotherapy of Cancer, GAAP, Licensure, ORR, University, Cancer, Anti-CD19 immunotoxin, Therapy, Patient, Lymphoma, ASCO, B-cell lymphoma, Congress, Conference, Cytopenia, ASH, Immunotherapy, Dor, Cytokine release syndrome, Follicular lymphoma, Society, MD Anderson Cancer Center, Investigational New Drug, Kite Pharma, AACR, IND, Incidence, FC, American Society of Clinical Oncology, RCC, Poster, General counsel, Vaccine, Pharmaceutical industry

Following the close of the third quarter, the Company announced Geoffrey Parker as Executive Vice President, Chief Financial Officer, overseeing the Company’s financial operations and business development activities.

Key Points: 
  • Following the close of the third quarter, the Company announced Geoffrey Parker as Executive Vice President, Chief Financial Officer, overseeing the Company’s financial operations and business development activities.
  • Research and development expenses were $46.0 million for the third quarter of 2023, which includes $6.7 million of non-cash stock-based compensation expense.
  • General and administrative expenses were $17.0 million for the third quarter of 2023, which includes $8.6 million of non-cash stock-based compensation expense.
  • Allogene will host a live conference call and webcast today at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss financial results and provide a business update.

Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, September 13, 2023
Good manufacturing practice, Incentive program, WSE, Congress, QP, Patient, United States Commercial Service, SE, Disease, Warsaw Stock Exchange, Research, USD, European Hematology Association, International Conference on Afghanistan, London (2010), CGMP, Hematology, ADC, Phase, Conference, Venetoclax, Safety, BioNTech, WIG20, Exelixis, API, History, Fibrosis, Pancreatic serous cystadenoma, Contract research organization, MA, Therapy, Splenomegaly, Cost, EDC, Data management, Good, ABM, AML, EHA, Dietary supplement, Pharmaceutical industry, Cryptocurrency

Updated clinical and preclinical data on RVU120 were presented at the European Hematology Associated (EHA) Congress in June 2023.

Key Points: 
  • Updated clinical and preclinical data on RVU120 were presented at the European Hematology Associated (EHA) Congress in June 2023.
  • $14M in non-dilutive grant funding was secured from the Medical Research Agency (ABM) – the largest grant obtained to date by Ryvu.
  • KRAKOW, Poland, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, reported today financial results for the first half of 2023 and provided a corporate update.
  • “The last months of 2023 were a productive period for Ryvu as we made significant developments across our clinical programs, collaboration activity, and strengthening our balance sheet”, said Pawel Przewiezlikowski, CEO of Ryvu Therapeutics.

Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Monday, August 14, 2023
Waldenström macroglobulinemia, Partnership, Mayo Clinic, Arm, CD19, Chronic lymphocytic leukemia, Follicular lymphoma, CRS, Fred Hutchinson Cancer Research Center, CD20, European Hematology Association, Clinical trial, Lymphoma, Research, History, Translation, WM, CAR, Waldenström, Acquisition, International Conference on Afghanistan, London (2010), Cytokine release syndrome, Patient, Cancer, CR, Clinical professor, Immunoglobulin M, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mustang, Conference, ORR, DSM-IV codes, Food, Safety, Disease, Pharmaceutical industry, Cryptocurrency, Video game

WORCESTER, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2023.

Key Points: 
  • WORCESTER, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2023.
  • Research and development expenses were $10.8 million for the second quarter of 2023, compared to $15.2 million for the second quarter of 2022.
  • Non-cash, stock-based expenses included in research and development were $(0.1) million for the second quarter of 2023, compared to $0.4 million for the second quarter of 2022.
  • General and administrative expenses were $3.1 million for the second quarter of 2023, compared to $3.1 million for the second quarter of 2022.

MiNK Therapeutics Reports Second Quarter 2023 Results

Retrieved on: 
Thursday, August 10, 2023
Shortness of breath, AACR, Gene, Cell therapy, ATS, COVID-19, Survival, Cancer, FAP, NSCLC, Inflammation, American Thoracic Society, International Conference on Afghanistan, London (2010), Patient, Memorial Sloan Kettering Cancer Center, Annual general meeting, Mink, Testicular cancer, Cell, American Society of Gene and Cell Therapy, Periodic breathing, Pembrolizumab, Therapy, Stomach, IND, Society, Conference, Nivolumab, Medical imaging, Vaccine, Pharmaceutical industry

NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today provided a corporate update and reported financial results for the second quarter 2023.

Key Points: 
  • The trial is planned to be fully externally funded and expected to accrue quickly with an anticipated launch in early 3Q2023.
  • These include responses and durable disease stabilization in patients with gastric cancer, NSCLC, testicular cancer, and beyond.
  • MiNK also plans to advance agenT-797 in patients with viral ARDS through an externally funded platform trial.
  • We ended the second quarter 2023 with a cash balance of $10.6 million as compared to $14.9 million in March 31, 2023, and $19.6 million at December 31, 2022.

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results

Retrieved on: 
Tuesday, August 8, 2023
Call, Total, TCL, PRS, ALC, BioRxiv, RCC, Neoplasm, KCRC, ITK, Lymphoma, Clinical trial, Extranodal NK/T-cell lymphoma, nasal type, Head, ICB, NSCLC, Cell, Lung cancer, Time management, Preprint, Colon, ATM, American Association for Cancer Research, International Conference on Afghanistan, London (2010), Japanese Cancer Association, Patient, Ipilimumab, Melanoma, Blood, Cancer, Kidney cancer, CR, Webcast, Research, FDA, Pembrolizumab, PR, Safety, Nivolumab, Communications satellite, Pharmaceutical industry, Cryptocurrency, Corvus, Conference

BURLINGAME, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the second quarter ended June 30, 2023.
  • The latest data from the trial was reported at the International Conference on Malignant Lymphoma, which took place June 13-17, 2023 in Lugano, Switzerland.
  • Based on its current plans, Corvus expects its cash to fund operations into the second half of 2024.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the second quarter 2023 financial results.

Galecto Reports Second Quarter Operating and Financial Results

Retrieved on: 
Monday, July 31, 2023
Molecule, Insurance, Idiopathic disease, Inhalation, Idiopathic pulmonary fibrosis, NASH, ATS, Cancer, NSCLC, Lung cancer, Fibrosis, International Conference on Afghanistan, London (2010), HIV disease progression rates, Patient, Investment, Fatty liver disease, Biology, Poster, Research, FDA, IPF, Cirrhosis, Conference, NIH, Safety, Pharmaceutical industry, Galecto Biotech

BOSTON, July 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter ended June 30, 2023.

Key Points: 
  • BOSTON, July 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter ended June 30, 2023.
  • “Galecto has made strong clinical progress in the first half of the year, setting the stage for several important milestones during the rest of 2023.
  • We completed dosing in our Phase 2b GALACTIC-1 trial of GB0139 in idiopathic pulmonary fibrosis in May and topline results are expected in August.
  • The company anticipates that its cash, cash equivalents and investments will be sufficient to fund operating expenses and capital requirements into the second half of 2024.

Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials

Retrieved on: 
Wednesday, June 14, 2023
STAT3, Plasmablastic lymphoma, Follicular lymphoma, IRAK4, DLBCL, Relapse, ICML, Immunomodulatory imide drug, Aes, Lymphoma, TPD, Biomarker, B-cell lymphoma, PBMC, Leukemia, International Conference on Afghanistan, London (2010), Patient, Plasma, MYD88, Cancer, ABC, Poster, Toxicity, Infrared spectroscopy correlation table, Therapy, Conference, Safety, Bone marrow, Vaccine, Pharmaceutical industry, Engineered wood, Medical imaging, Aeolus, Black Majesty

WATERTOWN, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today shared new data demonstrating that its oncology programs KT-333 and KT-413 continue to demonstrate robust dose-dependent target knockdown in ongoing Phase 1a dose escalation clinical trials, with no dose limiting toxicities (DLTs) observed. The KT-333 clinical data will be presented in a poster at the International Conference on Malignant Lymphoma (ICML) on June 16, 2023, in Lugano, Switzerland.

Key Points: 
  • The KT-333 clinical data will be presented in a poster at the International Conference on Malignant Lymphoma (ICML) on June 16, 2023, in Lugano, Switzerland.
  • “We are proud and excited to be the first company to have shown clinical translation of our degraders’ profiles across three programs and across multiple diseases and indications.
  • Data reported from the 3 completed dose levels (DL1-3) found:
    Plasma exposure increased with dose, reaching levels close to those predicted to be efficacious.
  • KT-413 achieved dose-dependent degradation of up to 70% IRAK4 and 96-100% Ikaros and Aiolos in PBMC after a single dose.

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

Retrieved on: 
Wednesday, May 24, 2023
COL1A1, Mahru, Therapy, ITGB6, Serum, ATS, VIM, Vanderbilt University Medical Center, FVC, Biomarker, Fibroblast, American Thoracic Society, QLF, White lung, Fibrosis, Vital capacity, International Conference on Afghanistan, London (2010), HIV disease progression rates, SAN, IPF, Death, Gene, Conference, Idiopathic pulmonary fibrosis, Pharmaceutical industry, Vaccine, Medicine

“Data presented at this year’s ATS conference highlight some of the strong foundational work conducted and encouraging interim clinical results from our Phase 2a INTEGRIS-IPF trial that warrant the progression of bexotegrast into late-stage clinical development,” said Éric Lefebvre, M.D., Chief Medical Officer at Pliant Therapeutics.

Key Points: 
  • “Data presented at this year’s ATS conference highlight some of the strong foundational work conducted and encouraging interim clinical results from our Phase 2a INTEGRIS-IPF trial that warrant the progression of bexotegrast into late-stage clinical development,” said Éric Lefebvre, M.D., Chief Medical Officer at Pliant Therapeutics.
  • In an oral presentation, Lisa H. Lancaster, M.D., Professor of Medicine at Vanderbilt University Medical Center and principal investigator of the INTEGRIS-IPF Phase 2a trial, reviewed 12-week data from the trial.
  • Results from a differential gene expression analysis suggest the mechanism of action of bexotegrast may be both independent of, and complementary to, that of currently approved therapies.
  • Results also demonstrated the utility of combining single cell transcriptomic techniques with fibrotic human tissue to evaluate the mechanism of action of novel anti-fibrotic therapies, such as bexotegrast.

ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
Monday, May 15, 2023
PMN, Therapy, File, PROMIS, Frontotemporal lobar degeneration, AAN, Multiple system atrophy, American Academy, RACK1, Antibody, DSM-IV codes, International Conference on Afghanistan, London (2010), Data, MSA, Neuroscience, Drug development, Amyloid, TSX, Research, AD, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, ALS, Neurology, Conference, Food, Pharmaceutical industry, Vaccine, Cryptocurrency

Last week, we announced that the FDA cleared our IND for PMN310 in Alzheimer’s disease, which is an exciting milestone for ProMIS,” said Gail Farfel, Ph.D., Chief Executive Officer of ProMIS Neurosciences.

Key Points: 
  • Last week, we announced that the FDA cleared our IND for PMN310 in Alzheimer’s disease, which is an exciting milestone for ProMIS,” said Gail Farfel, Ph.D., Chief Executive Officer of ProMIS Neurosciences.
  • Cash and cash equivalents were $3.3 million as of March 31, 2023, compared to $5.9 million as of December 31, 2022.
  • Research and development expenses were $3.5 million for the quarter ended March 31, 2023, compared to $1.9 million for the same period in 2022.
  • Net loss was $5.0 million for the quarter ended March 31, 2023, compared to $2.1 million for the same period in 2022.